Abstract Library

#4422 A case report of an undifferentiated neuroendocrine carcinoma with an unknown primary site

Introduction: In the situation where the primary lesion remains unknown, high-grade poorly differentiated neuroendocrine carcinoma typically shows extensive metastasis at the time of clinical visit. Common metastatic sites include the liver, bones, lungs and brain, and the prognosis is extremely poor.

Conference:

Presenting Author:

Authors: Lv J, Tang Y,

Keywords: poorly differentiated neuroendocrine carcinoma, unknown primary origin,

#4365 Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the stomach: A case report

Introduction: Gastric neuroendocrine tumours (NETs) are rare neoplasms that arise from enterochromaffin cells of the gastric mucosa. Neuroendocrine carcinoma (NEC) of the stomach represent a rare and rapidly growing type of gastric tumour. They are considered a distinct entity from neuroendocrine tumours characterised by aggressive behaviour and a high rate of metastasis.

Conference:

Presenting Author: Zidane H

Authors: Zidane H, Kebbati Z, Benkada M,

Keywords: neuroendocrine carcinoma, stomach, chemotherapy,

#3879 Molecular characterization of extrapulmonary, advanced neuroendocrine carcinomas and mixed adeno-neuroendocrine carcinomas – The NIRVANA study

Introduction: Extrapulmonary (EP) poorly differentiated neuroendocrine carcinomas (NECs) and mixed adeno-neuroendocrine carcinomas (MANECs) are aggressive neoplasms with dismal prognosis.

Conference:

Presenting Author: Spada F

Authors: Spada F, Pisa E, Ranghiero A, Frassoni S, Bagnardi V,

Keywords: poorly differentiated, extrapulmonary, NGS, NEC, biomarker, NEN,

#3846 Poorly differentiated neuroendocrine carcinomas – Characteristics, treatments and outcomes from a population-based cohort discussed in our ENETS-CoE institute

Introduction: Poorly differentiated neuroendocrine carcinomas (NECs) are rare malignancies with a dismal prognosis, few therapeutic options available and lacking predictive factors.

Conference:

Presenting Author: Benini L

Authors: Benini L, Spada F, Gervaso L, Borghesani M, Rubino M,

Keywords: Neuroendocrine Carcinoma, NEC,

#3536 Comparison of drug sensitivity profiles of various NEN spheroids

Introduction: Neuroendocrine neoplasms (NENs) are rare cancers that arise from neuroendocrine cells. NENs are classified as well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Small bowel and pancreatic NETs (SBNET & PNETs) are generally slow-growing but commonly metastasize to the liver and become aggressive cancers. Little is known about the drug sensitivity profile of these 3 NENs due to the lack of cellular and animal models of these malignancies. Recently, we have developed a protocol to culture NEN cells from patient tumors as patient-derived spheroids (PDS) and showed expression of NEN markers. The rarity and slow growing features of these spheroids have been hindering drug screens with many compounds.

Conference:

Presenting Author: Ear P

Authors: Tran C, Luis B, Sherman S, Mudd J, Abusada E,

Keywords: NET, NEC, spheroid, drug screening, PDX model,